Glassman Wealth Services’s Amneal Pharmaceuticals AMRX Stock Holding History

Glassman Wealth Services’s Portfolio AMRX Stock Details AMRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-325	Closed	-$1K	–	1922
2022 Q3	$1K	Buy	+325	New	+$911	﹤0.01%	1323

Other funds holding AMRX

Fosun International Hong Kong, China $446M AUM 13.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Glassman Wealth Services's AMRX Position: Q4 2022 in Review

Glassman Wealth Services sold out of Amneal Pharmaceuticals (AMRX) in Q4 2022, closing a stake of 325 shares — an estimated $1K sold.

Glassman Wealth Services first reported a position in AMRX in Q3 2022 and held it in 1 quarter. The position peaked at $1K in Q3 2022. 156 funds tracked by Wall St. Rank hold AMRX as of Q4 2022.

Glassman Wealth Services reported no remaining Amneal Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
Glassman Wealth Services sold 325 Amneal Pharmaceuticals shares in Q4 2022, an estimated $1K.
Glassman Wealth Services first reported a position in Amneal Pharmaceuticals in Q3 2022 and held it in 1 quarter.
Glassman Wealth Services's Amneal Pharmaceuticals position peaked at $1K in Q3 2022.
156 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q4 2022.

Based on Glassman Wealth Services's 13F filing for Q4 2022, filed 6 Feb 2023.